Immunomedics to Present At 50th ASH Annual Meeting Dec 2, 2008
--"Radioimmunotherapy of Non-Hodgkin Lymphoma is Improved without Increasing Toxicity by Combination with Antibody Immunotherapy" (Publication No. 1588, Session Name: Lymphoma: Pre-Clinical - Chemotherapy and Biologic Agents Poster I, Saturday, December 6, 5:30 p.m. - 7:30 p.m., Board # I-693, Moscone Center, Hall A) --"A Novel Anti-CD20 IgG-Interferon-alpha2b Fusion Protein with Potent in Vitro and in Vivo Anti-Lymphoma Activity Made by the Dock-and-Lock (DNL) Method" (Publication No. 1590,... (Primezone Releases)
Promacta Approved for Rare Blood Disorder Nov 26, 2008
Chronic immune thrombocytopenic purpura (ITP) affects about 60,000 people in the United States, according to a news release from the drug's maker, GlaxoSmithKline. ITP patients often bleed from small blood vessels, resulting in bruising, nosebleeds and in rare cases, bleeding from the brain. (MEDLINEplus)
FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder Nov 21, 2008
George, JN. Management of patients with refractory immune thrombocytopenic purpura. J Thromb. (PR Newswire)
FDA clears Glaxo blood-clotting drug Promacta Nov 21, 2008
The Food and Drug Administration cleared the drug for patients with chronic immune thrombocytopenic purpura, in which the body attacks its own platelets. The condition, which can cause bruising and bleeding after minor injuries, affects about 140,000 people in the U.S. and Europe. (BusinessWeek)
Rigel Announces Third Quarter 2008 Financial Results and Clinical Update Nov 3, 2008
The exploratory Phase 2a clinical trial in immune thrombocytopenic purpura (ITP) is ongoing and we expect the results to be published in the next couple of months. Rigel has deferred initiating any further trials in ITP until a collaboration partner for R788 is in place. (PR Newswire)
Leukemia drug halts MS Oct 26, 2008
The monitoring committee stopped the alemtuzumab arm of the trial early in September 2005 after three of the patients developed immune thrombocytopenic purpura ... The adverse events in the alemtuzumab group, as compared with the interferon beta-1a group, included autoimmune thyroid disorders (23% versus 3%] and immune thrombocytopenic purpura (3% versus 1%) ... They note that it was associated with autoimmunity, and this showed itself, most seriously, as immune thrombocytopenic purpura. (NHS Choices)
Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis Oct 23, 2008
In September 2005, alemtuzumab therapy was suspended after immune thrombocytopenic purpura developed in three patients, one of whom died ... Adverse events in the alemtuzumab group, as compared with the interferon beta-1a group, included autoimmunity (thyroid disorders [23% vs. 3%] and immune thrombocytopenic purpura [3% vs. 1%]) and infections (66% vs. 47%) ... Conclusions In patients with early, relapsing remitting multiple sclerosis, alemtuzumab was more effective than interferon beta-1a but... (New England Journal of Medicine)
FDA approves Amgen drug for some treatment of rare blood problem Aug 27, 2008
Thousand Oaks-based Amgen s (NASDAQ: AMGN) drug can now be sold in the United States as a treatment for a rare blood disorder, chronic immune thrombocytopenic purpura. The FDA said the drug may be used only after other treatments have been tried and have failed. (East Bay Business Times, CA)
FDA approves Amgen's blood platelet booster Aug 25, 2008
The injectable drug helps stimulate bone marrow into producing blood platelets in patients with chronic immune thrombocytopenic purpura (ITP), the FDA said. The agency approved its use for patients only after other available treatments fail to help. (Reuters)
Amgen's Nplate Wins U.S. FDA's Approval to Treat a Rare Bleeding Disorder Aug 23, 2008
The weekly injection, Nplate, treats immune thrombocytopenic purpura or ITP, a disease that causes the immune system to attack platelets in the blood, making patients vulnerable to bruising and severe bleeding, the FDA said today in an e-mailed. Outsider advisers to the agency had voted unanimously in favor of approval at a March 12 meeting. (Bloomberg -- US)
'IT'S VERY SERIOUS': Cordova woman diagnosed with TTP wants to raise awareness about the rare blood disorder Jun 3, 2008
I have an aunt who had ITP (immune thrombocytopenic purpura), the lesser version of TTP," said Cleckley, who has been taken off prednisone and chemotherapy. "My dad had a blood disorder. He passed away in August of 2007. (Orangeburg Times and Democrat, SC)
Immunomedics Reports High Anti-Lymphoma Potency With Veltuzumab Jun 2, 2008
We plan to submit preliminary results from this study, as well as the study in patients with immune thrombocytopenic purpura (ITP), to this year's annual meeting of the American Society of Hematology for presentation,'' commented Cynthia L. Sullivan, President and CEO. ``We are progressing towards our near term goal of completing the out-licensing of veltuzumab,'' she further remarked ... In addition, the Company is conducting clinical trials with intravenous veltuzumab in patients with NHL and... (Primezone Releases)
Immunomedics' Pretargeting Method May Improve Radioimmunotherapy of Cancer Apr 14, 2008
In addition, the Company is conducting clinical trials with intravenous veltuzumab in patients with NHL and immune thrombocytopenic purpura, subcutaneous veltuzumab in NHL and chromic lymphocytic leukemia (CLL), 90Y-epratuzumab for the therapy of patients with lymphoma, 90Y-hPAM4 combined with gemcitabine for pancreatic cancer therapy, and milatuzumab (anti-CD74 humanized antibody) as a therapy for patients with multiple myeloma, NHL, and CLL. We also have a majority ownership in IBC... (Primezone Releases)
Immunomedics' Product Candidates Being Presented At 2008 American Association for Cancer Research Annual Meeting Apr 10, 2008
In addition, the Company is conducting clinical trials with intravenous veltuzumab in patients with NHL and immune thrombocytopenic purpura, subcutaneous veltuzumab in NHL and chromic lymphocytic leukemia (CLL), (90)Y-epratuzumab for the therapy of patients with lymphoma, (90)Y-hPAM4 combined with gemcitabine for pancreatic cancer therapy, and milatuzumab (anti-CD74 humanized antibody) as a therapy for patients with multiple myeloma, NHL, and CLL. We also have a majority ownership in IBC... (Primezone Releases)
The Panelling on Amgen's Walls Mar 18, 2008
Amgen's first positive outcome in recent memory from an FDA advisory panel hearing came Tuesday, after a panel voted unanimously to recommend approval of its immune thrombocytopenic purpura (ITP) treatment, Romiplostim. ITP is the cause of those purple bruises on some elderly people's arms and is a result of low blood platelet count. (MSNBC -- Business)
Immunomedics' Milatuzumab Receives FDA Orphan Drug Designation for Therapy of Multiple Myeloma Mar 18, 2008
The Company is conducting clinical trials with veltuzumab in patients with non-Hodgkin's lymphoma and immune thrombocytopenic purpura, epratuzumab as a potential therapeutic for patients with lymphoma and leukemia, 90Y-epratuzumab for the therapy of patients with lymphoma, 90Y-hPAM4 for pancreas cancer therapy and milatuzumab as a therapy for patients with multiple myeloma, non-Hodgkin's lymphoma, and chronic lymphocytic leukemia. We believe that our portfolio of intellectual property, which... (Primezone Releases)
Effective Treatment Found For Hepatitis C Patients With Low Blood-platelet Counts, Study Suggests Jan 6, 2008
With other eltrombopag findings, NewYork-Presbyterian/Weill Cornell's Dr. James Bussel led research, also reported in the New England Journal of Medicine, finding the platelet growth factor successfully increased platelet counts and decreased bleeding in patients with Immune Thrombocytopenic Purpura (ITP), an autoimmune disease that dramatically reduces the number of platelets in their blood ... 29, 2007) There are estimated to be between 50,000-100,000 individuals in the US diagnosed with... (Science Daily)
Hospital failed to detect babys death, says teacher Dec 14, 2007
Khairul said his wife suffered from Immune thrombocytopenic purpura that causes low blood palette count, and she was hospitalised several times during the last two months. He said he was giving the hospital a week to explain, failing which he would take legal action. (The Star Online, Malaysia -- News)
UPDATE 1-Amgen study shows platelets response with Nplate Dec 12, 2007
LOS ANGELES, Dec 10 (Reuters) - Amgen Inc AMGN.O said on Monday its experimental drug AMG 531 had the desired effect of increasing platelet production in adults with a bleeding disorder known as chronic immune thrombocytopenic purpura. The Phase 3 trial of the drug, also known as Nplate or romiplostim, studied 62 ITP patients who had failed previous treatments. (Reuters)
Cephalon, Celgene Kick Off ASH Confab Dec 11, 2007
12/8/2007 9:18 PM ESTIn a phase III trial, the treatment increased platelets in patients with Immune Thrombocytopenic Purpura. Biotech. (TheStreet.com)
Research Highlights New Approaches to Management of Blood Clotting and Bleeding Disorders Dec 9, 2007
ATLANTA, Dec. 8 /PRNewswire-USNewswire/ -- Data that shed new light on the treatment of residual vein thrombosis, thromboprophylaxis after total hip replacement, chronic immune thrombocytopenic purpura, and venous thrombosis in relation to postmenopausal hormone replacement therapy will be presented at the 49th Annual Meeting of the American Society of Hematology in Atlanta, GA. A press conference will reveal this new research on Saturday, December 8, from 10:00 to 11:00 a.m. "Complications... (PR Newswire)
Pivotal Phase 3 Romiplostim Study in Splenectomized Patients Meets Primary Endpoints Dec 9, 2007
Data Show Romiplostim Increased and Sustained Platelet Counts in Splenectomized Adult Patients with Immune Thrombocytopenic Purpura. ATLANTA--()--Amgen Inc. (NASDAQ:AMGN) today announced results from a randomized, pivotal Phase 3 study that showed romiplostim (AMG 531) increased and sustained platelet counts in splenectomized (spleen removed) adult patients with chronic Immune Thrombocytopenic Purpura (ITP). (BusinessWire)
Amgen study shows romiplostim boosts platelets Dec 9, 2007
LOS ANGELES (Reuters) - Amgen Inc said on Saturday that a late-stage trial of its experimental drug AMG 531 showed it boosted and sustained platelet counts in adults with chronic immune thrombocytopenic purpura, a bleeding disorder. The Phase 3 Amgen-sponsored trial included 63 chronic ITP patients, who had their spleens removed after other treatments had failed. (ABC News -- Wire)
Pill Boosts Platelets In Hepatitis C Patients Nov 30, 2007
29, 2007) There are estimated to be between 50,000-100,000 individuals in the US diagnosed with chronic Immune Thrombocytopenic Purpura, an autoimmune disease that dramatically reduces the number of platelets. (Sep. (Science Daily)
Immune Thrombocytopenic Purpura — From Agony to Agonist Nov 29, 2007
NEJM -- Immune Thrombocytopenic Purpura -- From Agony to Agonist ... Immune Thrombocytopenic Purpura From Agony to Agonist. (New England Journal of Medicine)
Eltrombopag studied in Idiopathic Thrombocytopenic Purpura Nov 29, 2007
29, 2007) -- There are estimated to be between 50,000 -- 100,000 individuals in the U.S. diagnosed with chronic Immune Thrombocytopenic Purpura (ITP), an autoimmune disease that dramatically reduces the number of platelets in their blood -- causing bruises, nosebleeds and, sometimes, life-threatening brain hemorrhages ... Immune thrombocytopenic purpura (ITP) is an autoimmune disease in which anti-platelet antibodies accelerate destruction of platelets. (EurekAlert!)
Bearing her soul: RBV's Crabtree works to brighten lives of young cancer patients Nov 13, 2007
She was hospitalized with immune thrombocytopenic purpura, a syndrome in which one's blood has difficulty clotting because of an unusually low number of platelets. Crabtree said she contracted scarlet fever, strep throat and chicken pox at the same time. (North County Times)
Genzyme gets OK to resume testing of MS drug May 17, 2007
He said the clinical trial so far has yielded five other cases of the bleeding disorder, called immune thrombocytopenic purpura , or ITP. All of those patients were treated and recovered. With early detection and treatment, the problem amounts to a "manageable risk" for Campath patients, said the company. (Boston Globe)
AMG 531 for Chronic ITP Jan 18, 2007
19 issue)1 justify the rationale for using the thrombopoiesis-stimulating drug AMG 531 in chronic immune thrombocytopenic purpura (ITP) by citing previous reports on abnormalities of megakaryocytic survival and maturation in this disorder. However, studies of defective platelet production in ITP have yielded conflicting results,2,3 and the present study provides no evidence of such an abnormality in any patient. (New England Journal of Medicine)
Rigel starts mid-stage trial of blood disorder treatment Jan 9, 2007
The South San Francisco company (NASDAQ: RIGL) is testing the product, R788, for treatment of patients with refractory immune thrombocytopenic purpura. It is a blood disorder in which the immune system attacks platelets. (San Francisco Business Journal)
